LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET

Belén Mezquita; Estela Pineda; Jovita Mezquita; Pau Mezquita; Montserrat Pau; Jordi Codony-Servat; Eva Martínez-Balibrea; Conchi Mora; Joan Maurel; Cristóbal Mezquita

doi:10.1002/mc.22289

journal article Feb 03, 2015

LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET

Jovita Mezquita Pau Mezquita Montserrat Pau Jordi Codony-Servat Eva Martínez-Balibrea Conchi Mora Joan Maurel Cristóbal Mezquita

Molecular Carcinogenesis Vol. 55 No. 5 pp. 411-419 · Wiley

View at Publisher Save 10.1002/mc.22289

Topics

No keywords indexed for this article. Browse by subject →

References

46

[1]

Weitz "Colorectal cancer" Lancet (2005) 10.1016/s0140-6736(05)17706-x

[2]

Rabik "Molecular mechanisms of resistance and toxicity associated with platinating agents" Cancer Treat Rev (2007) 10.1016/j.ctrv.2006.09.006

[3]

de Gramont "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer" J Clin Oncol (2000) 10.1200/jco.2000.18.16.2938

[4]

Saltz "Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study" J Clin Oncol (2008) 10.1200/jco.2007.14.9930

[5]

Martinez-Cardús "Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer" Mol Cancer Ther (2009) 10.1158/1535-7163.mct-08-0659

[6]

Virag "Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins" BMC Genomics (2013) 10.1186/1471-2164-14-480

[7]

Ma "C-Met: Structure, functions and potential for therapeutic inhibition" Cancer Metastasis Rev (2003) 10.1023/a:1023768811842

[8]

Gao "Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma" Med Oncol (2013) 10.1007/s12032-013-0546-3

[9]

Jankowski "Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy" Cancer Res (2003)

[10]

Bellusci "Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity" Oncogene (1994)

[11]

Jeffers "Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis" J Mol Med (Berl) (1996) 10.1007/bf00204976

[12]

Takayama "Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor" Proc Natl Acad Sci U S A (1997) 10.1073/pnas.94.2.701

[13]

Gallego "Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways" Oncogene (2003) 10.1038/sj.onc.1207063

[14]

Jiang "Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer" Crit Rev Oncol Hematol (1999) 10.1016/s1040-8428(98)00019-5

[15]

Yashiro "A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma" Br J Cancer (2013) 10.1038/bjc.2013.638

[16]

Marchion "A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth" Oncol Rep (2013) 10.3892/or.2013.2329

[17]

Tang "C-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2" Neoplasia (2010) 10.1593/neo.91438

[18]

Fan "Role of Src signal transduction pathways in scatter factor-mediated cellular protection" J Biol Chem (2009) 10.1074/jbc.m807497200

[19]

Bachelder "Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4" Cancer Res (2002)

[20]

Ahluwalia "Aberrant, ectopic expression of VEGF and VEGF receptors 1 and 2 in malignant colonic epithelial cells. Implications for these cells growth via an autocrine mechanism" Biochem Biophys Res Commun (2013) 10.1016/j.bbrc.2013.06.096

[21]

Fan "Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells" Mol Cancer Ther (2008) 10.1158/1535-7163.mct-08-0615

[22]

Hurwitz "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer" N Engl J Med (2004) 10.1056/nejmoa032691

[23]

Fan "Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration" Br J Cancer (2011) 10.1038/bjc.2011.81

[24]

Lu "VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex" Cancer Cell (2012) 10.1016/j.ccr.2012.05.037

[25]

Quante "No functional and transductional significance of specific neuropilin 1 siRNA inhibition in colon carcinoma cell lines lacking VEGF receptor 2" Oncol Rep (2009) 10.3892/or_00000336

[26]

Naik "Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant {beta}-Catenin Activation in Colon Cancer" Clin Cancer Res (2009) 10.1158/1078-0432.ccr-09-0336

[27]

PI3K/Akt signalling pathway and cancer

Juan Ángel Fresno Vara, Enrique Casado, Javier de Castro et al.

Cancer Treatment Reviews 2004 10.1016/j.ctrv.2003.07.007

[28]

Nemoto "Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation" J Biol Chem (2009) 10.1074/jbc.m900735200

[29]

Xie "Inhibition of Tcf-4 induces apoptosis and enhances chemosensitivity of colon cancer cells" PLoS ONE (2012) 10.1371/journal.pone.0045617

[30]

Chao "Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance" Clin Exp Metastasis (2012) 10.1007/s10585-011-9427-3

[31]

Nakamura "E-cadherin-dependent intercellular adhesion enhances chemoresistance" Int J Mol Med (2003)

[32]

Plasencia "Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells" Int J Oncol (2006)

[33]

Mezquita "A novel intracellular isoform of VEGFR-1 activates Src and promotes cell invasion in MDA-MB-231 breast cancer cells" J Cell Biochem (2010) 10.1002/jcb.22584

[34]

Wallmen "Intrinsic properties of Tcf1 and Tcf4 splice variants determine cell-type-specific Wnt/β-catenin target gene expression" Nucleic Acids Res (2012) 10.1093/nar/gks690

[35]

MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis

Keun Hur, Yuji Toiyama, Masanobu Takahashi et al.

Gut 2013 10.1136/gutjnl-2011-301846

[36]

Yang "Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines" Clin Cancer Res (2006) 10.1158/1078-0432.ccr-06-0038

[37]

Ren "Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents" Cancer Cell (2004) 10.1016/s1535-6108(04)00020-0

[38]

Ren "MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90" Oncogene (2006) 10.1038/sj.onc.1209012

[39]

Rajabi "MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 expression in human breast cancer cells" J Biol Chem (2012) 10.1074/jbc.m111.323311

[40]

Kim "E-cadherin inhibits nuclear accumulation of Nrf2: implications for chemoresistance of cancer cells" J Cell Sci (2012) 10.1242/jcs.095422

[41]

Rodriguez "E-cadherin's dark side: possible role in tumor progression" Biochim Biophys Acta (2012)

[42]

Pece "Activation of the protein kinase Akt/PKB by the formation of E-cadherin-mediated cell-cell junctions. Evidence for the association of phosphatidylinositol 3-kinase with the E-cadherin adhesion complex" J Biol Chem (1999) 10.1074/jbc.274.27.19347

[43]

Howard "A positive role of cadherin in Wnt/β-catenin signalling during epithelial-mesenchymal transition" PLoS ONE (2011) 10.1371/journal.pone.0023899

[44]

HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation

David Liska, Chin-Tung Chen, Thomas Bachleitner-Hofmann et al.

Clinical Cancer Research 2011 10.1158/1078-0432.ccr-10-0568

[45]

Kim "Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells" Neuro Oncol (2013) 10.1093/neuonc/nos299

[46]

Bendell "Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer" Clin Colorectal Cancer (2013) 10.1016/j.clcc.2013.04.001

Metrics

13

Citations

46

References

Details

Published: Feb 03, 2015
Vol/Issue: 55(5)
Pages: 411-419
License: View

Authors

B

Belén Mezquita

Departament de Ciències Fisiològiques I. Laboratori de Genètica Molecular, IDIBAPS, Facultat de Medicina; Universitat de Barcelona; Barcelona Spain; Departament de Ciències Bàsiques; Universitat Internacional de Catalunya; Barcelona Spain

E

Estela Pineda

Medical Oncology Department; Hospital Clínic; University of Barcelona; Barcelona Spain

J

Jovita Mezquita

Departament de Ciències Fisiològiques I. Laboratori de Genètica Molecular, IDIBAPS, Facultat de Medicina; Universitat de Barcelona; Barcelona Spain

P

Pau Mezquita

Departament de Ciències Bàsiques; Universitat Internacional de Catalunya; Barcelona Spain

M

Montserrat Pau

Departament de Ciències Fisiològiques I. Laboratori de Genètica Molecular, IDIBAPS, Facultat de Medicina; Universitat de Barcelona; Barcelona Spain

J

Jordi Codony-Servat

Medical Oncology Department; Hospital Clínic; University of Barcelona; Barcelona Spain

E

Eva Martínez-Balibrea

Medical Oncology Service; Institut Català d'Oncologia-Hospital Germans Trias i Pujol; Badalona Spain

C

Conchi Mora

Departament de Medicina Experimental; Universitat de Lleida, Alcalde Rovira Roure; Lleida Spain

J

Joan Maurel

Medical Oncology Department; Hospital Clínic; University of Barcelona; Barcelona Spain

C

Cristóbal Mezquita

Departament de Ciències Fisiològiques I. Laboratori de Genètica Molecular, IDIBAPS, Facultat de Medicina; Universitat de Barcelona; Barcelona Spain

Funding

MarÃa Francisca de Roviralta Foundation

Cite This Article

Belén Mezquita, Estela Pineda, Jovita Mezquita, et al. (2015). LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET. Molecular Carcinogenesis, 55(5), 411-419. https://doi.org/10.1002/mc.22289

LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET

You May Also Like